Reuters logo
REFILE-India's Ranbaxy narrows Q4 loss on U.S. acne drug sales
February 5, 2014 / 6:50 AM / 4 years ago

REFILE-India's Ranbaxy narrows Q4 loss on U.S. acne drug sales

MUMBAI, Feb 5 (Reuters) - Ranbaxy Laboratories Ltd , India’s biggest generic drugmaker by revenue, reported a narrower net loss in the latest quarter helped by ramped-up sales of two acne drugs in the United States.

Ranbaxy, majority owned by Japan’s Daiichi Sankyo Co Ltd , on Wednesday said net loss in October-December was 1.59 billion rupees ($25.39 million) compared with a loss of 4.92 billion rupees a year earlier.

Net sales rose 7 percent to 28.59 billion rupees, the company said in a statement.

The United States, Ranbaxy’s biggest export market, has recently banned the import of drugs from the company’s India plants due to quality concerns.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below